"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Descriptor ID |
D055728
|
| MeSH Number(s) |
C15.378.190.636.765
|
| Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Fibrosis, Bone Marrow
- Myelofibrosis
- Myelofibroses
- Idiopathic Myelofibrosis
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Chronic Idiopathic Myelofibrosis
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Myelofibrosis With Myeloid Metaplasia
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in this website by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles.
-
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022 05 05; 139(18):2797-2815.
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
-
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).
-
Ruxolitinib Discontinuation Syndrome in a Patient With Myelofibrosis to Acute Myeloid Leukemia Transformation. JCO Oncol Pract. 2020 07; 16(7):395-396.
-
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019 05; 33(5):1287-1291.
-
A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis. Pediatr Blood Cancer. 2017 Sep; 64(9).
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
-
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2016 Sep; 27(6):648-52.
-
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Am J Pathol. 2012 Sep; 181(3):858-65.
-
A technique to detect reduced mechanical stability of red cell membranes: relevance to elliptocytic disorders. Blood. 1982 Apr; 59(4):768-74.